Providers

DLBCL expert Lunning weighs radiation consolidation after R-CHOP and spotlights Epkinly and SKYGLO bispecific trials, plus access and infection risks.

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

After CAR T-cell therapy relapse in mantle cell lymphoma, an antibody drug conjugate regimen adapted from DLBCL shows durable remission.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

Shahzad Mian, MD, explains dry eye disease symptoms, key risk factors, and practical management strategies like drops and warm compresses.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

Women with PMOS had more than 4 times the adjusted ASCVD risk of matched peers, and traditional risk factors explained only about a third of the gap.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

GLP-1 use in adolescents and young adults with obesity rose to 96.1% as bariatric surgery fell by two-thirds, new JAMA Pediatrics data show.

Case series suggests glofitamab bridges relapsed mantle cell lymphoma to CAR T, with strong responses and mostly low-grade CRS.

New data suggest epcoritamab plus R2 may win insurer coverage, delivering major QALY gains at approximately $68,000 and delaying costly progression.

US drug shortages rose to 227 in Q2 2026, led by a severe ifosfamide shortage.

This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited patient involvement, and barriers to care coordination.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

6 leading AI chatbots scored below 28% on a colorectal cancer knowledge test when barred from reasoning, raising fresh safety concerns for clinical use.

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.